ReviewOncogene2007
Targeting death-inducing receptors in cancer therapy.
Review in Oncogene, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 182 citations in OpenAlex.
- Article
- TRAIL-dependent apoptosis of peritoneal mesothelial cells by NK cells promotes ovarian cancer invasion.iScience · 2023Article
- ST6Gal1: Oncogenic signaling pathways and targets.Frontiers in molecular biosciences · 2022Review
- Postoperative Natural Killer Cell Dysfunction: The Prime Suspect in the Case of Metastasis Following Curative Cancer Surgery.International journal of molecular sciences · 2021Review
- Review
- First-in-human DR5 PET reveals insufficient DR5 expression in patients with gastrointestinal cancer.Journal for immunotherapy of cancer · 2021Article
- Trimer form of tumor necrosis factor-related apoptosis inducing ligand induces apoptosis in canine cell lines derived from mammary tumors.The Journal of veterinary medical science · 2019Article
- Procaspase-3 Overexpression in Cancer: A Paradoxical Observation with Therapeutic Potential.ACS chemical biology · 2019Review
- Review
- Differential expression of senescence tumour markers and its implications on survival outcomes of breast cancer patients.PloS one · 2019Article
- Galla Rhois water extract inhibits lung metastasis by inducing AMPK‑mediated apoptosis and suppressing metastatic properties of colorectal cancer cells.Oncology reports · 2019Article
- Lactate dehydrogenase A promotes the invasion and proliferation of pituitary adenoma.Scientific reports · 2017Article
- Metformin inhibits proliferation and growth hormone secretion of GH3 pituitary adenoma cells.Oncotarget · 2017Article
- First-in-human study of the antibody DR5 agonist DS-8273a in patients with advanced solid tumors.Investigational new drugs · 2017Article
- Downregulation of DcR3 sensitizes hepatocellular carcinoma cells to TRAIL-induced apoptosis.OncoTargets and therapy · 2017Article
- Emerging Strategies for Developing Next-Generation Protein Therapeutics for Cancer Treatment.Trends in pharmacological sciences · 2016Review
- Molecular signaling cascades involved in nonmelanoma skin carcinogenesis.The Biochemical journal · 2016Review
- Icariside II overcomes TRAIL resistance of melanoma cells through ROS-mediated downregulation of STAT3/cFLIP signaling.Oncotarget · 2016Article
- Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies.Blood · 2016Review
- miR-143 or miR-145 overexpression increases cetuximab-mediated antibody-dependent cellular cytotoxicity in human colon cancer cells.Oncotarget · 2016Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Deregulated cell death pathways may lead to the development of cancer, and induction of tumor cell apoptosis is the basis of many cancer therapies. Knowledge accumulated concerning the molecular mechanisms of apoptotic cell death has aided the development of new therapeutic strategies to treat cancer. Signals through death receptors of the tumor necrosis factor (TNF) superfamily have been well elucidated, and death receptors are now one of the most attractive therapeutic targets in cancer. In particular, DR5 and DR4, death receptors of TNF-related apoptosis-inducing ligand (TRAIL or Apo2L), are interesting targets of antibody-based therapy, since TRAIL may also bind decoy receptors that may prevent TRAIL-mediated apoptosis, whereas TRAIL ligand itself selectively induces apoptosis in cancer cells. Here, we review the potential therapeutic utility of agonistic antibodies against DR5 and DR4 and discuss the possible extension of this single-antibody-based strategy when combined with additional modalities that either synergizes to cause enhanced apoptosis or further engage the cellular immune response. Rational design of antibody-based therapies combining the induction of tumor cell apoptosis and activation of tumor-specific adaptive immunity enables promotion of distinct steps of the antitumor immune response, thereby enhancing tumor-specific lymphocytes that can eradicate TRAIL/DR5-resistant mutating, large established and heterogeneous tumors in a manner that does not require the definition of individual tumor-specific antigens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.